Chronic Δ 9-tetrahydrocannabinol treatment in rhesus monkeys: Differential tolerance and cross-tolerance among cannabinoids

British Journal of Pharmacology

Volumn 162, Issue 5, 2011, Pages 1060-1073

  McMahon, Lance R ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

cannabinoid; cross tolerance; drug discrimination; efficacy; fixed ratio responding; rhesus monkey; tolerance

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; DRONABINOL; KETAMINE; MIDAZOLAM; RIMONABANT; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; BENZOXAZINE DERIVATIVE; CANNABINOID; CYCLOHEXANOL DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAHYDROCANNABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; MALE; NONHUMAN; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; RHESUS MONKEY; SENSORY STIMULATION; ANIMAL; COMPARATIVE STUDY; DISCRIMINATION LEARNING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG TOLERANCE; MACACA MULATTA; PHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; CANNABINOIDS; CYCLOHEXANOLS; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; MACACA MULATTA; MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 79551486841     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01116.x     Document Type: Article

References (43)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158: S1-S254.
2. Ariens EJ, (1954). Affinity and intrinsic activity in the theory of competitive inhibition. Arch Int Pharmacodyn Ther 99: 32-49.
3. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN, (2000). Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology 153: 67-84.
4. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272: 22330-22339.
5. Brandt MR, France CP, (2000). Chronic l-alpha-acetylmethadol (LAAM) in rhesus monkeys: tolerance and cross-tolerance to the antinociceptive, ventilatory, and rate-decreasing effects of opioids. J Pharmacol Exp Ther 294: 168-178.
6. Breivogel CS, Childers SR, (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295: 328-336.
7. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2459.
8. De Vry J, Jentzsch KR, (2004). Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm. Behav Pharmacol 15: 13-20.
9. 9-THC on learning in rats. Pharmacol Biochem Behav 74: 129-140.
10. 9-tetrahydrocannabinol. Biochem Pharmacol 22: 399-405.
11. 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271: 1383-1390.
12. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND, (1999). Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288: 478-483.
13. Goldberg SR, Schuster CR, (1967). Conditioned suppression by a stimulus associated with nalorphine in morphine-dependent monkeys. J Exp Anal Behav 10: 235-242.
14. He L, Fong J, von Zastrow M, Whistler JL, (2002). Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108: 271-282.
15. 1 receptor-mediated signal transduction. Br J Pharmacol 142: 1209-1218.
16. Hunt CA, Jones RT, (1980). Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215: 35-44.
17. 9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol 466: 121-127.
18. Kenakin TP, (1981). An in vitro quantitative analysis of the alpha adrenoceptor partial agonist activity of dobutamine and its relevance to inotropic selectivity. J Pharmacol Exp Ther 216: 210-219.
19. Kenakin T, (1997). Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven Publishers: Philadelphia.
20. Kenakin T, (2002). Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42: 349-379.
21. 9- tetrahydrocannabinol in man. Science 170: 1320-1322.
22. 9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs. J Pharmacol Exp Ther 196: 128-144.
23. Martini L, Whistler JL, (2007). The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17: 556-564.
24. 9- tetrahydrocannabinol. J Pharmacol Exp Ther 324: 664-673.
25. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 319: 1211-1218.
26. 9-tetrahydrocannabinol. Psychopharmacology 203: 219-228.
27. A modulators on schedule-controlled responding in rhesus monkeys. J Pharmacol Exp Ther 300: 1017-10125.
28. 9-trans-tetrahydrocannabinol in pigeons: tolerance to the behavioral effects. Science 169: 501-503.
29. 9-tetrahydrocannabinol and its metabolites in tolerant and nontolerant pigeons. Biochem Pharmacol 22: 383-397.
30. 9-tetrahydrocannabinol in rats: effect on social interactions, mouse killing, motor activity, consummatory behavior, and body temperature. Psychopharmacology 60: 137-146.
31. National Research Council (1996). Guide for the Care and Use of Laboratory Animals. National Academy Press: Washington, DC.
32. Palmer SL, Thakur GA, Makriyannis A, (2002). Cannabinergic ligands. Chem Phys Lipids 121: 3-19.
33. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
34. Sannerud CA, Allen M, Cook JM, Griffiths RR, (1991). Behavioral effects of benzodiazepine ligands in non-dependent, diazepam-dependent, and diazepam-withdrawn baboons. Eur J Pharmacol 202: 159-169.
35. Siemens AJ, Kalant H, (1974). Metabolism of delta1-tetrahydrocannabinol by rats tolerant to cannabis. Can J Physiol Pharmacol 52: 1154-11566.
36. 9-tetrahydrocannabinol on cannabinoid- stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16: 8057-8066.
37. Stephenson RP, (1956). A modification of receptor theory. Br J Pharmacol 11: 379-393.
38. 9- THC withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 334: 347-356.
39. Tallarida RJ, (2000). Drug Synergism and Dose-Effect Data Analysis. Chapman and Hall/CRC: Boca Raton, FL.
40. Walker EA, Young AM, (1993). Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine. J Pharmacol Exp Ther 267: 322-330.
41. Walker EA, Makhay MM, House JD, Young AM, (1994). In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271: 959-968.
42. Walker EA, Richardson TM, Young AM, (1997). Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats. Psychopharmacology 133: 17-28.
43. 9-tetrahydrocannabinol. Behav Pharmacol 4: 581-585.